NCT05373212View on ClinicalTrials.gov

A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

January 2, 2023

Study Completion Date

January 2, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

Euglycemic clamp with BC Combo THDB0207

Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.

DRUG

Euglycemic clamp with Humalog® Mix25

Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Adocia
All Listed Sponsors
collaborator

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY

lead

Adocia

INDUSTRY

NCT05373212 - A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter